Daré Bioscience, Inc., a biopharmaceutical company, has announced positive interim results from its ongoing Phase 3 clinical trial of Ovaprene®, an investigational hormone-free, monthly intravaginal contraceptive. The study aims to evaluate the contraceptive effectiveness, safety, and acceptability of Ovaprene. Interim findings revealed that approximately 9% of participants experienced pregnancy, aligning with the company's expectations from previous studies. No serious safety concerns were identified, with favorable overall tolerability reported. The study's Data Safety Monitoring Board recommended continuing the trial without modifications. Final results and analysis of study endpoints, including the pregnancy rate calculated using the Pearl Index, are anticipated upon the study's completion. Currently, there are no FDA-approved hormone-free, monthly intravaginal contraceptives on the market.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。